Preterm delivery, Fetal Neuroprotection Paediatrics
Conditions
Interventions
NeuroProtect QI Program
Control
Sponsors
Ayokunle Moses Olumodeji
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthcare Providers: 1. Obstetricians, midwives, nurses, and other maternity staff directly involved in the management of preterm deliveries and the administration of MgSO4. 2. Providers who have worked in the participating hospitals for at least 6 months to ensure familiarity with local practices. 3. Willingness to participate in training sessions, audits, and interviews or focus group discussions. Hospitals: 1. General hospitals in Lagos State with maternity units that manage preterm deliveries. 2. Hospitals with a minimum annual delivery rate of 500 births to ensure sufficient data for analysis. 3. Hospitals willing to participate in all phases of the study (baseline audit, barrier identification, intervention implementation, and post-intervention audit). Patients: 1. Pregnant women at risk of imminent preterm delivery (gestational age between 24 and 34 weeks) who are eligible for MgSO4 administration according to standard guidelines.
Exclusion criteria
Exclusion criteria: Healthcare Providers: 1. Providers who are not directly involved in the management of preterm deliveries or the administration of MgSO4. 2. Providers who are temporary staff or have been working in the hospital for less than 6 months. 3. Providers who are unwilling to participate in the study or attend training sessions. Hospitals: 1. Hospitals that already have a well-established protocol for routine MgSO4 administration for fetal neuroprotection. 2. Hospitals with insufficient infrastructure to support the intervention (e.g., lack of basic obstetric care facilities). 3. Hospitals unwilling to comply with the study requirements or ethical guidelines.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in proportion of eligible pregnant women (at risk of imminent preterm delivery between 24 and 34 weeks gestation) who receive antenatal MgSO4 for fetal neuroprotection post-intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Adherence to Evidence-Based Guidelines: The proportion of healthcare providers following standardized protocols for MgSO4 administration. 2. Knowledge and Confidence of Healthcare Providers: Improvement in providers’ knowledge and confidence in administering MgSO4, measured through pre- and post-intervention surveys. 3. Neonatal Outcomes: Potential reduction in the incidence of cerebral palsy associated with preterm birth. 4. Barrier Reduction: Decrease in identified barriers to MgSO4 administration (e.g., lack of knowledge, supply chain issues). | — |
Countries
Nigeria
Contacts
Public ContactAyokunle Olumodeji
Consultant Obstetrician and Gynaecologist
Outcome results
None listed